Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
No. 1 Xiaoqian Prescription
- Development stage
- Unknown
- Lead developer
- Xiyuan Hospital
- Administration
- Oral
01
Overview
No. 1 Xiaoqian Prescription (also known as Xiao Chuan No. 1) is a Traditional Chinese Medicine (TCM) hospital preparation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically formulated for the treatment of bronchial asthma and wheezing, particularly during the chronic or remission phases. The prescription is based on the clinical experience of renowned TCM practitioners at Xiyuan Hospital and is designed to tonify the lungs and kidneys, transform phlegm, and relieve wheezing. In clinical practice, it is often used to regulate the immune system, specifically by balancing Th1/Th2 cytokines and reducing serum IgE levels, thereby decreasing airway hyperresponsiveness and the frequency of acute exacerbations. It is a well-known component of the 'winter diseases treated in summer' (Dong Bing Xia Zhi) therapeutic protocols in China.
- Other names
- Xiao Chuan Yi Hao Fang消喘1号方Xiaoqian No. 1
02
Targets
IL-4 (Interleukin 4)IFNG (Interferon gamma)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on No. 1 Xiaoqian Prescription.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on No. 1 Xiaoqian Prescription.